



PATENT  
ATTORNEY DOCKET NO. 01997/211003

Certificate of Mailing: Date of Deposit: January 16, 2002

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202.

Moya Kinnealey

Printed name of person mailing correspondence

Moya Kinnealey  
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	H. Robert Horvitz et al.	Art Unit:	Not yet assigned
Serial No.:	09/888,243	Examiner:	Not yet assigned
Filed:	June 22, 2001	Customer No.:	21559
Title:	RELATEDNESS OF HUMAN INTERLEUKIN-1 $\beta$ CONVERTASE GENE TO A <i>C. ELEGANS</i> CELL DEATH GENE, INHIBITORY PORTIONS OF THESE GENES AND USES THEREFOR		

U.S. Patent and Trademark Office  
Box Sequence, P.O. Box 2327  
Arlington, VA 22202

DECLARATION OF KRISTINA BIEKER-BRADY, PH.D.

I, Kristina Bieker-Brady, Ph.D., state as attorney of record for the above-referenced patent application, and as a Registered Patent Attorney, the following:

1. The amino acid sequence of SEQ ID NO: 28 in the Amended Sequence Listing filed herewith is the amino acid sequence of murine NEDD-2 in Fig. 2 of Fernandes-Alnemri *et al.*, *J. Biol. Chem.* 269:30761, 1994, a copy of which is enclosed with an enlarged version of Fig. 2. As indicated on page 32, lines 7-10, of the specification, this publication is incorporated by reference in the present application as a part of the definition of asp-ase proteases of the invention. As the amino acid sequence of SEQ ID NO: 28 is the same as that of the sequence incorporated by reference, this amendment contains no new matter.

2. In the preliminary amendment filed herewith, the numbering of the amino acid residues of the NEDD-2 proteins recited in claims 9-13 and 16 has been amended to correspond to the amino acid numbering of the NEDD-2 sequence of SEQ ID NO: 28. As illustrated in the sequence alignment of Exhibit A, residues 43, 44, 46, 67, 82, 97, 102, 103, 108, 122, 158, 163, and 166 of SEQ ID NO: 13 recited in claim 12 as filed (top sequence) correspond to residues 323, 324, 326, 327, 362, 377, 282, 383, 386, 388, 402, 438, 443, and 446, respectively, of SEQ ID NO: 28 recited in amended claim 12 (bottom sequence). Similarly, residue 117 of SEQ ID NO: 26 recited in claim 9 as filed corresponds to residue 397 of SEQ ID NO: 28 recited in amended claim 9.

The sequence alignment of Exhibit B indicates that the catalytic cysteine 303 of the NEDD-2 sequence deposited in Genbank as accession number P29594 (bottom sequence) corresponds to cysteine 319 of the NEDD-2 sequence of SEQ ID NO: 28, which has additional amino acids because of an earlier translation start site (top sequence). Thus, cysteine 319 of the NEDD-2 sequence of SEQ ID NO: 28, which is recited in amended claims 10, 11, 13, and 16, corresponds to the active site cysteine of NEDD-2.

Date:

*January 16, 2002*

*Kristina Bieker-Brady*  
\_\_\_\_\_  
Kristina Bieker-Brady  
Reg. No. 39,109

F:\01997\01997.211003 Declaration.wpd



21559

PATENT TRADEMARK OFFICE

Exhibit A

Seq1 Seq2 Similarity Consensus  
01997.11003. seq id 13 with ala 01997.11003.seq id 28 Index Length  
(27>171) (307>451) 89.7 145

↕30	↕40	↕50	↕60	↕70	↕80	↕90	↕100	↕110
LGTSFCSLLPPPLLLYE	DRGVDDQDDGKNHTQSPGCEESDAGKEELMKMRLPTRSD	MICGYACLKGNAA	MNTKR	SWY	IEALTQVFSER			
L	DRGVDDQDDGKNHTQSPGCEESDAGKEELMKMRLPTRSD	MICGYACLKGNAA	MNTKR	SWY	IEALTQVFSER			
LONKPKMFFIQACRGDE	DRGVDDQDDGKNHTQSPGCEESDAGKEELMKMRLPTRSD	MICGYACLKGNAA	MNTKR	SWY	IEALTQVFSER			
↕310	↕320	↕330	↕340	↕350	↕360	↕370	↕380	↕390
↕120	↕130							
CDMHVADMLVKVNALIKEREGYAPGTEFHRCKEMSEYCS	TE	COQL	LFPGY	PPT				
CDMHVADMLVKVNALIKEREGYAPGTEFHRCKEMSEYCS	TE	COQL	LFPGY	PPT				
CDMHVADMLVKVNALIKEREGYAPGTEFHRCKEMSEYCS	TE	COQL	LFPGY	PPT				
↕400	↕410							



Ktuple: 2; Gap Penalty: 4; Gap Length Penalty: 12

Seq1(1>451)	Seq2(1>435)	Similarity	Gap	Gap	Consensus	
01997.11003.seq id 28	01997.211003.nedd-2	Index	Number	Length	Length	
(18>451)	(1>435)	99.5	1	1	435	
↙20	↙30	↙40	↙50	↙60	↙70	↙80
MAADRRSRILAVCGMHPDHQETLKKNRVVLAKQLLLSELLEHLLEKDIITLEMRELIOAKGGSFSQNVE-						
MAADRRSRILAVCGMHPDHQETLKKNRVVLAKQLLLSELLEHLLEKDIITLEMRELIOAKGGSFSQNVE						
MAADRRSRILAVCGMHPDHQETLKKNRVVLAKQLLLSELLEHLLEKDIITLEMRELIOAKGGSFSQNVEL						
↖10	↖20	↖30	↖40	↖50	↖60	↖70
↙90	↙100	↙110	↙120	↙130	↙140	↙150
LNLLPKRGPQAFDAFCEALRETROGHLEDLLLTTLSDIQHVLPLSCDYDTSLPFSVCESCPPHKQLRLS						
LNLLPKRGPQAFDAFCEALRETROGHLEDLLLTTLSDIQHVLPLSCDYDTSLPFSVCESCPPHKQLRLS						
LNLLPKRGPQAFDAFCEALRETROGHLEDLLLTTLSDIQHVLPLSCDYDTSLPFSVCESCPPHKQLRLS						
↖80	↖90	↖100	↖110	↖120	↖130	↖140
↙160	↙170	↙180	↙190	↙200	↙210	↙220
TDATEHSLDNGDGPPCLLVKPCTPEFYQAHYQLAYRLQSQPRGLALVLSNVHFTGEKDLEFRSGGDVDHT						
TDATEHSLDNGDGPPCLLVKPCTPEFYQAHYQLAYRLQSQPRGLALVLSNVHFTGEKDLEFRSGGDVDHT						
TDATEHSLDNGDGPPCLLVKPCTPEFYQAHYQLAYRLQSQPRGLALVLSNVHFTGEKDLEFRSGGDVDHT						
↖150	↖160	↖170	↖180	↖190	↖200	↖210
↙230	↙240	↙250	↙260	↙270	↙280	↙290
TLVTLFKLLGYNVHVLHDQTAQEMQEKLNFAQLPAHRVTDSCVVALLSHGVEGGIYGVDGKLLQLQEVF						
TLVTLFKLLGYNVHVLHDQTAQEMQEKLNFAQLPAHRVTDSCVVALLSHGVEGGIYGVDGKLLQLQEVF						
TLVTLFKLLGYNVHVLHDQTAQEMQEKLNFAQLPAHRVTDSCVVALLSHGVEGGIYGVDGKLLQLQEVF						
↖220	↖230	↖240	↖250	↖260	↖270	↖280
↙300	↙310	↙320	↙330	↙340	↙350	↙360
RLFDNANCPSLQNKPKMFFIQALRGDETDRGVDQQDGKNHTQSPGCEESDAGKEELMKMRLPTRSDMICG						
RLFDNANCPSLQNKPKMFFIQALRGDETDRGVDQQDGKNHTQSPGCEESDAGKEELMKMRLPTRSDMICG						
RLFDNANCPSLQNKPKMFFIQALRGDETDRGVDQQDGKNHTQSPGCEESDAGKEELMKMRLPTRSDMICG						
↖290	↖300	↖310	↖320	↖330	↖340	↖350
↙370	↙380	↙390	↙400	↙410	↙420	↙430
YACLKGNAAMRNTKRGSWYIEALTQVFSERACDMHVADMLVKVNALIKEREGYAPGTEFHRCKEMSEYCS						
YACLKGNAAMRNTKRGSWYIEALTQVFSERACDMHVADMLVKVNALIKEREGYAPGTEFHRCKEMSEYCS						
YACLKGNAAMRNTKRGSWYIEALTQVFSERACDMHVADMLVKVNALIKEREGYAPGTEFHRCKEMSEYCS						
↖360	↖370	↖380	↖390	↖400	↖410	↖420
↙440	↙450					
TLCQQLYLFPGYPPT						
TLCQQLYLFPGYPPT						
TLCQQLYLFPGYPPT						
↖430						